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http://dx.doi.org/10.1016/j.jfma.201Baseline and on-treatment hepatitis B viral factors are reported to affect treatment responses.
A lower baseline hepatitis B virus (HBV) DNA level is a strong predictor of the response to anti-
viral therapy. HBV genotype A/B patients have better responses to interferon-based therapy
than those with genotypes C/D. Regarding the association of HBV mutants with responses to
antiviral therapy, current evidence is limited. On-treatment viral suppression is the most
important predictor of response to nucleoside analogs. On-treatment hepatitis B surface anti-
gen decline is significantly associated with response to pegylated interferon. In the future,
individualized therapy should be based on treatment efficacy, adverse effects, baseline and
on-treatment predictors of antiviral therapy.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Hepatitis B virus (HBV) is an important public health
problem and the leading cause of chronic hepatitis,stitute of Clinical Medicine,
of Medicine, 1, Chang-Te
(J.-H. Kao).
ight ª 2013, Elsevier Taiwan LLC
3.02.001cirrhosis, and hepatocellular carcinoma (HCC) worldwide.
The long-term outcomes of chronic HBV infection vary
widely. For example, the annual incidence rate of cirrhosis
is estimated to be 2e6% for hepatitis B e antigen (HBeAg)-
positive and 8e10% for HBeAg-negative patients. The life-
time risk of HBV carriers to develop cirrhosis, liver failure,
or HCC may be as high as 15e40%.1e3 Therefore, the
development of effective antiviral agents to delay or even
halt the progression from chronic hepatitis to cirrhosis and& Formosan Medical Association. All rights reserved.
Viral predictors of CHB therapy 303eventually HCC is urgently needed. According to the rec-
ommendations of the American Association for the Study of
Liver Disease (AASLD), the European Association for the
Study of Liver (EASL), and the Asian Pacific Association for
the study of liver (APASL), the evaluation tests for the in-
dications of HBV therapy include quantitative serum HBV
DNA level, alanine aminotransferase (ALT) level and/or
histological severity. The clinical assessment to monitor
treatment responses entails sustained suppression of HBV
replication, biochemical remission, histological improve-
ment, HBeAg/hepatitis B surface antigen (HBsAg) loss or
seroconversion for HBeAg-positive patients, and ideally
HBsAg loss or seroconversion for HBeAg-negative
patients.4e6 Previous investigations into the molecular
epidemiology of HBV and therapeutic development have
led to significant advances in the treatment of chronic
hepatitis B (CHB). In this article, hepatitis B viral factors
influencing responses to anti-HBV therapy will be reviewed
and discussed.Therapeutic efficacy of current antiviral
agents
At present, seven agents have been globally approved for
the treatment of CHB, they are standard interferon (IFN)-a
or polyethylene glycol (PEG)ylated IFN-a (PEG-IFN-a), with
mainly immune modulatory effects, and five nucleos(t)ide
analogs (NAs) with direct antiviral effects, including lam-
ivudine (LAM), telbivudine (LdT), entecavir (ETV), adefovir
dipivoxil (ADV) and tenofovir disoproxil fumarate (TDF).
Recent updates of AASLD, EASL, and APASL management
guidelines recommended PEG-IFN-a, ETV and TDF as the
preferred first-line agents.4e6 Clinical effectiveness of
these agents in treatment-naı¨ve patients is summarized in
Table 1.Table 1 Clinical efficacy of 1-year (48 weeks or 52 weeks) ant
controlled trial.
Efficacy LAM ADV
HBeAg-positive patients
Log10HBV DNA decline 5.54 3.5
HBV DNA undetectable (%) 36e40 13e21
ALT normalization (%) 60e75 48e54
Histologic improvement (%) 56e62 53e68
HBeAg seroconversion (%) 18e21.5 12e18
HBsAg seroconversion (%) 1 0
HBeAg-negative patients
Log10HBV DNA decline 4.5 3.9
HBV DNA undetectable (%) 72 51e63
ALT normalization (%) 71e79.3 72e77
Histologic improvement (%) 61e66 64e69
HBsAg loss (%) <1 0
ADVZ adefovir dipivoxil; ALTZ alanine aminotransferase; CHBZ chr
HBsAg Z hepatitis B surface antigen; HBV Z hepatitis B virus; LAM Z
a Z pegylated interferon-a; TDF Z tenofovir disoproxil fumarate.
a Rates of suppression of HBV DNA to below 400 copies/mL at 24 w
b Efficacy was assessed at 24 weeks after 48 weeks of treatment.Immunomodulatory agents
Standard IFN-a
The first approved antiviral agent for CHB, induces dual
antiviral effects through the degradation of viral messenger
RNA to inhibit protein synthesis and the enhancement of
host natural killer as well as cytotoxic T cell activities.7 The
mechanisms of IFN-a response for HBeAg-positive and
-negative patients are different. For HBeAg-positive pa-
tients, IFN-a induces an early reduction of HBV replication
and a late (about 2 months later) increase in serum ALT
levels. Thus, HBeAg seroconversion can be achieved,
following a hepatitis flare-up, before or within 6 months of
the end of IFN-a therapy.8 However, HBeAg-negative CHB
patients have replicating HBV DNA in the presence of anti-
HBe immunity. In those patients, efficient control of HBV
infection is achieved through sustained suppression of HBV
replication.9 A meta-analysis showed that standard IFN-a
therapy can induce serum ALT normalization, loss of HBeAg,
sustained suppression of serum HBV DNA as measured by
non-polymerase chain reaction (PCR) assays and clearance
of HBsAg by 25%, 25%, 23%, and 6%, respectively, in HBeAg-
positive patients.10 In HBeAg-negative patients treated
with standard IFN-a, the combined persistent serum ALT
normalization and suppression of serum HBV DNA as
measured by non-PCR assays was achieved in 10e47% of
patients.11,12 However, viral relapse occurred in about half
of initial responders after cessation of IFN treatment.13PEG-IFN-a
With an attachment of inert PEG polymer to standard IFN,
PEG-IFN-a shows a longer half-life than standard IFN-a.14 In
HBeAg-positive patients, 1 year of PEG-IFN a-2a and -2biviral agent therapy in treatment-naı¨ve CHB in a randomized
LdT ETV TDF PEG-IFN-a
6.45 6.9 6.4 4.5
60 67 76 14a
77 68 68 41b
64.7 72 74 38b
22.5 21 21 32b
NA 2 3.2 3e5b
5.2 5.0 4.7 4.1
88.3 90 93 19a
74.4 78 76 59b
66.6 70 72 48b
<1 NA 0 4b
onic hepatitis B; ETVZ entecavir; HBeAgZ hepatitis B e antigen;
lamivudine; LdT Z telbivudine; NA Z not available; PEG-IFN-
eeks after 48 weeks of treatment.
304 C.-L. Lin, J.-H. Kaomonotherapy led to HBeAg seroconversion in 32% and 29% of
patients at 6 months after therapy cessation, respectively.
In addition, HBsAg seroconversion was achieved in 3e5% of
patients at 6 months after therapy.15,16 Regarding HBeAg-
negative patients, a recent large multinational trial
revealed that combined response with serum ALT normali-
zation and <400 copies/mL of HBV DNA occurred in 15% of
patients treated for 1 year with PEG-IFN a-2a, and HBsAg
loss was reported in 4% at 6 months after therapy.17 After 4
years of follow-up, 17% of HBeAg-negative patients had
<400 copies/mL of HBV DNA as assessed by PCR assay. In
addition, HBsAg seroclearance progressively increased to
11%.18 The cumulating data suggest that PEG-IFN-a tends to
be superior to standard IFN-a for the treatment of CHB,
irrespective of HBeAg status.
Direct antiviral agents
LAM
As the first approved NA with intermediate antiviral po-
tency, LAM is the most widely used anti-HBV agent world-
wide. For HBeAg-positive patients, the HBeAg
seroconversion rate was improved from 18% to 65% after
1e5 years of LAM therapy.19e23 LAM therapy for 3 years also
reduced necro-inflammatory activity and reversed bridging
fibrosis in 57% and 65% of CHB patients, respectively.24 For
HBeAg negative patients, LAM achieved HBV DNA unde-
tectability in as many as 75% of CHB patients after 1 year of
therapy.25e27 However, due to the low genetic barrier to
the development of drug resistance, the incidence of LAM
resistance with subsequent virological breakthrough accu-
mulates with increasing duration of treatment, in 14%, 38%,
57%, 67%, and 70% of people after 1, 2, 3, 4, and 5 years,
respectively.19e22,28 Drug resistance to LAM sometimes in-
duces marked flare of serum ALT level or acute exacerba-
tion.29 However, a recent meta-analysis showed that the
risk of developing long-term complications including
decompensated cirrhosis, liver-related death or HCC was
substantially reduced in patients with long-term LAM
therapy than those without [relative risk (RR): 0.26, 95%
confidence interval (CI): 0.15e0.47]. Even in patients with
LAM resistance, the incidence of long-term complications
was also lower than those without treatment (RR: 0.55, 95%
CI: 0.40e0.76).30 In addition, Fasano et al recently re-
ported that HBsAg clearance was observed in 11.7% of pa-
tients responding to 5-year LAM monotherapy
(undetectable HBV DNA and without LAM-resistant muta-
tions) who continued to receive LAM monotherapy.31
Therefore, although the risk of LAM resistance-related
hepatitis flare-up may limit the popular use of LAM, long-
term LAM therapy still significantly achieves HBsAg clear-
ance, improves survival of CHB patients, and reduces the
risk of major complications compared with no antiviral
treatment.32
ADV
As a second proved NA for the treatment of CHB, ADV re-
sults in sustained reductions of serum HBV DNA level and is
associated with histological improvement in both HBeAg-positive and -negative patients. In HBeAg-positive patients,
21% of patients had undetectable serum HBV DNA after 48
weeks of ADV treatment. Rates of HBeAg loss and HBeAg
seroconversion were 24% and 12%, respectively.33 After 5
years of ADV treatment, rates of HBeAg loss and serocon-
version increased to 58% and 48%, respectively.34 In HBeAg-
negative patients, 51% of patients had undetectable serum
HBV DNA after 48 weeks of ADV treatment.35 After 5 years
of ADV treatment, 67% of patients had serum HBV DNA
levels of <1000 copies/mL.36
Compared with the low genetic barrier of LAM, ADV has
an intermediate genetic barrier to the development of drug
resistance. For treatment-naı¨ve CHB patients, no ADV-
associated resistant mutation was identified after 1 year
of treatment, regardless of HBeAg status.33,35 However, the
5-year cumulative probability of ADV resistance was 20%
and 29% for HBeAg-positive and HBeAg-negative patients,
respectively.34,36 Regarding the profile of adverse effects,
renal toxicity with an increase in serum creatinine level of
>0.5 mg/dL from baseline was observed in 8% of patients
treated with 5-year ADV.34LdT
LdT is a potent anti-HBV agent with no fetal toxic effects
in preclinical studies.37 Patients treated with LdT,
including HBeAg-positive and -negative patients, had a
significantly greater reduction of serum HBV DNA level
than those treated with LAM.27 Among HBeAg-positive
patients, HBeAg seroconversion was reached in 22.5% and
29.6% of patients after 1 and 2 years of LdT therapy,
respectively.27,38 Of particular note, 57% of HBeAg-positive
patients who maintained undetectable serum HBV DNA
during 3-year LdT treatment could achieve HBeAg sero-
conversion, and 6% of them lost serum HBsAg at the end of
3-year LdT therapy.39
Nevertheless, like LAM, virological response rates
decrease over time due to the emergence of drug resis-
tance to LdT. The frequency of LdT resistance increased
from 5.0% and 2.3% at 1 year to 25% and 11% at 2 years in
HBeAg-positive and HBeAg-negative patients, respec-
tively.27,38 In addition, LdT-resistant mutations have cross-
resistance with LAM,40 thus LdT is limited for the treatment
of patients with proven LAM resistance.ETV
ETV is a highly potent nucleoside inhibitor of HBV poly-
merase with a high genetic barrier to drug resistance.41,42
For treatment-naı¨ve HBeAg-positive patients, cumulative
rates of HBV suppression increased from 67% to 94% at 1 and
5 years of ETV treatment, respectively.43,44 HBeAg sero-
conversion occurred in 21% and 31% of patients at 1 and 2
years of ETV therapy, respectively.43,45 Of note, HBsAg loss
was confirmed in 5.1% HBeAg-positive patients after 2 years
of treatment.46 Similarly, 90% of HBeAg-negative patients
had undetectable serum HBV DNA after 48 weeks of ETV
treatment.26 In particular, histological evaluation after
long-term treatment with ETV (median time of biopsy:
6 years, range: 3e7 years) showed necro-inflammatory and
Viral predictors of CHB therapy 305fibrosis score improvement in 96% and 88% of patients,
respectively.47
In addition to a high potency of viral suppression, the
high barrier to drug resistance leads to a sustained viro-
logical response from ETV therapy. Among nucleoside-naı¨ve
patients treated with ETV, 7% of patients had viremia (300
copies/mL of HBV DNA) in year 5. However, the 5-year
cumulative probability of genotypic resistance and geno-
typic resistance-associated virologic breakthrough was only
1.2% and 0.8%.48 However, the genetic barrier to drug
resistance was substantially reduced and the rate of
genotypic resistance was 51% of patients with prior LAM
resistance at 5-year ETV treatment.48
TDF
TDF is the latest licensed agent for the treatment of
chronic HBV infection. The therapeutic effect remained
durable at 5 years of TDF treatment, 83% of HBeAg-negative
and 65% of HBeAg-positive patients had HBV DNA unde-
tectability. Overall histologic improvement occurred in 85%
of patients, including 75% of patients with cirrhosis at entry
who had regression of histologic cirrhosis at 5 years.49 The
virological breakthrough and persistent viremia on TDF
monotherapy were infrequent over 3 years (3% and 0.8%,
respectively). However, neither of them were associated
with virological resistance to TDF.50 Furthermore, no NA-
naı¨ve patients developed amino acid substitutions associ-
ated with drug resistance to TDF during 5 years of treat-
ment.49 By using systematic review and meta-analyses, Woo
et al reported that for HBeAg-positive patients, TDF was
most effective in inducing undetectable serum HBV DNA,
ALT normalization, HBeAg seroconversion, and HBsAg loss
with the predicted probability of 88%, 66%, 20%, and 5%,
respectively. Additionally, for HBeAg-negative patients,
TDF was most effective in inducing undetectable serum
HBV DNA and improving liver histology with the predicted
probability of 94% and 65%, respectively.51Table 2 Hepatitis B viral factors associated with response of a
IFN-based therapy
HBeAg-positive HBeAg-nega
Baseline
Viral load Low Low
Quantitative
HBsAg
No correlation No correlat
Genotype A>D and B>C A>non-A
HBV mutants
PC/BCP mutants Controversial Controversi
On-treatment
HBV DNA decline No correlation 2 log10 IU/
week 12
Quantitative
HBsAg decline
<1500 IU/ml at
week 12
10% declin
baseline at
12
BCP Z basal core promoter; HBeAg Z hepatitis B e antigen; HB
IFN Z interferon; NA Z nucleoside analog; PC Z pre-core.
a Telbivudine treatment.Combination of NAs with low genetic barrier
The major limitation of long-term NA therapy is the
development of drug resistance. For patients with drug
resistance to LAM and LdT, both are L-NAs with low genetic
barrier, the optimal treatment includes add-on TDF or shift
to TDF. The alternative treatment is add-on ADV.52 Several
studies further supported that add-on ADV to LAM in pa-
tients with LAM-resistance could result in effective HBV
suppression and induce maintained biochemical remission
with rare emergence of ADV-resistance as compared with
switching to ADV monotherapy.53e56 A recent meta-analysis
revealed that ADV in combination with LAM as a salvage
therapy for patients with LAM-resistance had lower emer-
gence rates of ADV-resistant HBV strains than ADV mono-
therapy (RR: 0.15, 95% CI: 0.03e0.74, p Z 0.02). In
addition, compared with ADV monotherapy, ADV plus LAM
had greater virological response rates (RR: 1.28, 95% CI:
1.10e1.49, p Z 0.002) as well as biochemical response
rates (RR: 1.18, 95% CI: 1.04e1.35, p Z 0.01).52
Factors influencing the response to antiviral
therapy
The mechanisms of antiviral activity have led to different
characteristics and suitability of patients for each type of
antiviral agent. Therefore, it is necessary to find out the
predictors of each medicine to improve its clinical out-
comes and tailor individualization of treatment. Currently,
several hepatitis B viral factors, which can be divided into
baseline and on-treatment factors, have been identified to
influence responses to antiviral therapies (Table 2).57
Baseline viral factors
Hepatitis B viral load. Serum HBV DNA level is the known
predictor of adverse clinical outcomes (cirrhosis, HCC, andntiviral agent therapy in chronic hepatitis B.
NA therapy
tive HBeAg-positive HBeAg-negative
Low Low
ion Controversial Controversial
No correlation No correlation
al Controversial Controversial
mL at Undetectable at
week 24
Undetectable at
week 24
e from
week
1 log10 IU/mL at
year 1a
No correlation
sAg Z hepatitis B surface antigen; HBV Z hepatitis B virus;
306 C.-L. Lin, J.-H. Kaodeath from liver disease) in adults with chronic HBV
infection.58e60 An earlier study using a summative analysis
of the literature also showed that pretreatment serum HBV
DNA level was significantly associated with efficacy of
antiviral therapy, including histological grading, serum ALT
normalization and incidence of HBeAg seroconversion.61
Furthermore, several clinical trials confirmed that a lower
baseline HBV DNA level was predictive of HBeAg loss or
seroconversion as well as viral suppression in patients
receiving antiviral therapy.15,16,62e66
Quantitative HBsAg levels. A quantitative assay for
serum HBsAg levels is currently available.67 The relation-
ships between HBsAg, intrahepatic HBV DNA and serum HBV
DNA concentration were quite distinct by HBeAg status. In
HBeAg-positive CHB, HBsAg level was positively correlated
with intrahepatic HBV DNA and serum HBV DNA concen-
tration. On the contrary, HBsAg level correlated poorly with
serum HBV DNA and did not correlate with intrahepatic HBV
DNA in HBeAg-negative CHB.68 With regard to clinical phe-
notypes, HBsAg levels were much higher in HBeAg-positive
patients in the immune tolerance and immune clearance
phase than HBeAg-negative patients.69,70 Our recent study
showed that HBeAg-negative patients with lower levels of
HBsAg have higher chances of losing HBsAg than those with
high levels.71 High levels of HBsAg increase the risk of HCC
in HBeAg-negative patients with low levels of serum HBV
DNA (<2000 IU/mL). The hazard ratio for HCC in patients
with levels of HBsAg  1000 vs. < 1000 IU/mL was 13.7 (95%
CI: 4.8e39.3).72 In addition, high HBsAg level (1000 IU/
mL) was also associated with HBeAg-negative hepatitis
development in those patients.73 These lines of evidence
indicate that there is a correlation between serum HBsAg
level and liver disease progression. Therefore, serum HBsAg
levels may serve as a predictor of efficacy during antiviral
therapy.
In two large multinational studies of patients treated
with PEG-IFN-a-2a, the baseline HBsAg level was not
correlated with antiviral response, regardless of HBeAg
status.74,75 Most recently, two studies on naı¨ve HBeAg-
positive patients treated with ETV for 2 years showed
that the association of baseline HBsAg level and treatment
response still remained controvesial.76,77 These lines of
evidence indicate that further studies are warranted to
validate the predictive value of baseline HBsAg levels for
responses to antiviral therapies.
HBV genotype. According to strains exhibiting an entire
genome sequence, divergence of >8% or 4e8%, at least 10
HBV genotypes (AeJ), and several subtypes have been
identified.78 The clinical and virological implications of HBV
genotypes bear geographic differences. The impact of HBV
genotype on the responses to both IFN-based and NA
treatments has been increasingly recognized.78 In HBeAg-
positive patients treated with standard IFN-a, the sus-
tained response rate of serum ALT level normalization and
HBeAg seroconversion post-treatment, is significantly bet-
ter in genotype A and B patients than genotype C and D
patients.79e81 A multicenter study on PEG-IFN-a for HBeAg-
positive patients also showed that the rate of HBeAg
clearance and durable loss of HBeAg at 3 years post-
treatment were higher in genotype A and B patients than
genotype C and D patients.82 In addition, genotype A and B
patients had a significant decline of serum HBsAg levelcompared with genotype C and D patients (p < 0.001)
during PEG-IFN-a therapy for HBeAg-positive patients.83
Among HBeAg-negative patients treated with PEG-IFN-a, a
long-term follow-up study further showed that HBsAg
seroclearance was significantly higher in genotype A (20%)
than non-A (6e9%) patients.84 A meta-analysis also
confirmed that HBV genotype A patients have better re-
sponses to IFN-a treatment than genotype D patients,
regardless of HBeAg status. Similarly, HBeAg-positive ge-
notype B patients have a higher response rate to IFN-a
treatment than genotype C patients.85 Recently, pooled
data from two large global trials of HBeAg-positive patients
treated with PEG-IFN-a showed that genotype A patients
with higher ALT levels or lower HBV DNA levels, as well as
genotype B and C patients having both higher ALT levels and
lower HBV DNA levels had a high predicted probability of a
sustained treatment response. On the contrary, genotype D
patients had the lowest chance of sustained response,
irrespective of ALT or HBV DNA levels.86
In sharp contrast to IFN-based therapy, differential re-
sponses to NAs among patients with different HBV geno-
types remain controversial.87e92 Although HBV genotype
seems to have no impact on the response to NA treatment,
our retrospective study showed that HBV genotype B was
independently associated with earlier emergence of LAM-
resistant strains than genotype C. In addition, genotype B
was significantly associated with development of LAM-
resistance within the first 12 months of LAM therapy
compared with genotype C (odds ratio (OR): 8.27;
p Z 0.004).93 Whether a given genotype is associated with
emergence of LAM resistance remains unclear, frequent
monitoring of genotypic resistance should be performed for
all patients during LAM therapy.
HBV mutants. Several common HBV mutant strains such
as mutations in the pre-core, core promoter and deletion
mutation in the pre-S/S genes have been reported to be
associated with progressive liver disease, including cirrhosis
and HCC.60 However, their impact on HBV treatment re-
mains largely unknown. A recent review showed that half of
the studies suggested that pre-core G1896A mutation or
basal core promoter (BCP) A1762T/G1764A mutation were
associated with the response to IFN-a or NA therapy.94 A
previous study on 116 HBeAg-positive CHB patients
receiving short-term LAM therapy showed that pre-core
G1896A mutation, compared with wild-type (75% vs. 52%,
pZ 0.045), correlated with the loss of HBeAg at the end of
therapy.95 Our recent study on 115 HBeAg-positive patients
receiving PEG-IFN-a-2a for 6 months indicated that BCP
A1762T/G1764A mutation was associated with a combined
response defined as HBeAg seroconversion, HBV DNA
level < 20,000 IU/mL as well as ALT normalization at 6
months after therapy cessation (OR: 8.04, 95% CI:
2.00e32.28).66 On the contrary, recent analysis of 214
HBeAg-positive patients receiving PEG-IFN-a with or
without LAM for 1 year revealed that patients without
presence of pre-core and BCP mutants at baseline were
more likely to achieve HBeAg loss with HBV DNA of <10,000
copies/mL (response, 34% vs. 11%, p < 0.001) and HBsAg
clearance (18% vs. 2%, p < 0.001) at 6 months after therapy
cessation than patients with the presence of pre-core or
BCP mutants. The wild-type of pre-core and BCP region of
virus at baseline was an independent predictor of response
Viral predictors of CHB therapy 307(OR: 2.90, 95% CI: 1.15e7.31, p Z 0.023) and HBsAg
clearance (OR 5.58, 95% CI: 1.26e24.63, p Z 0.013).96
Recently, we developed a new assay, PCR-
pyrosequencing, to quantify the pre-core G1896A and BCP
A1762T/G1764A mutant percentages. The correlation be-
tween dynamic changes of these mutants and IFN-induced
HBeAg seroconversion was further determined in 203
HBeAg-positive CHB patients. We found that the chance of
HBeAg seroconversion increased by 2.2% (OR: 1.022, 95% CI:
1.009e1.034, p Z 0.001) and 2.3% (OR: 1.023, 95% CI:
1.010e1.037, p Z 0.001) per 1% increase in the pretreat-
ment pre-core G1896A and BCP A1762T/G1764A mutants,
respectively.97 As relevant data are limited, additional
large-scale studies are required to examine the association
of common HBV mutants with treatment response to
currently available antiviral agents.On-treatment viral factors
Reduction of HBV DNA level. In recent years, early viral
suppression has been found to be the most important pre-
dictive factor of the antiviral efficacy of NAs. It was
confirmed that patients with a DNA level of <2000 IU/mL at
4 weeks of LAM therapy had the highest probability to reach
the ideal response (HBV DNA level < 400 IU/mL, HBeAg
seroconversion, normal ALT levels, and absence of LAM
resistance) after 5-year LAM treatment.98 Similar findings
were observed in both HBeAg-positive and -negative pa-
tients with LdT or LAM therapy, that undetectable serum
HBV DNA level at week 24 was associated with favorable
outcomes at week 52 in terms of virological, biochemical
responses and drug resistance.27 In patients with LAM
resistance who were treated with ADV, early viral sup-
pression was also a predictor for long-term favorable out-
comes. Patients with undetectable serum HBV DNA at 24
weeks had significantly higher virological response than
those with HBV DNA > 2000 IU/mL.99 For NA-naı¨ve, HBeAg-
positive patients on long-term ADV therapy, HBV DNA level
of <10,000 copies/mL at week 24 was predictive of viro-
logical response, as well as HBeAg seroconversion.100 In
addition, in patients with LAM resistance, achievement of
an on-treatment initial virological response at 6 months
(serum HBV DNA levels of <2000 copies/mL) was one of the
predictive factors for virological response after 5-year ADV
monotherapy.101 Unlike agents with modest antiviral po-
tency, the impact of early viral suppression on treatment
effect for highly potent NAs, such as ETV and TDF, is not
confirmed. For patients treated with ETV, early rapid
decline of viral load at day 10 was found to be predictive of
virological response with serum HBV DNA of <300 copies/
mL at week 48.102 All the evidence indicates that HBV viral
kinetics are the most important predictor of response and
drug resistance during NA therapy.103
Kinetics of quantitative HBsAg level. Recently, the on-
treatment decline of quantitative serum HBsAg level has
been proven to be useful as a predictor of response after
antiviral treatment. For HBeAg-positive patients, 1 year of
PEG-IFN-a with or without LAM resulted in a significantly
sustained decline of serum HBsAg level in patients with
HBeAg loss and HBV DNA of <10,000 copies/mL at 26 weeks
post-treatment compared with non-responders (decline atweek 52: 3.3 vs. 0.7 log IU/mL, p < 0.001). Patients
without any decline of serum HBsAg level at week 12 had a
97% probability of non-response and no chance of HBsAg
loss at the end of follow-up.74 A recent randomized
controlled trial also showed that on-treatment decline of
serum HBsAg level was significantly associated with post-
treatment HBeAg seroconversion in HBeAg-positive, geno-
type B and C patients treated with PEG-IFN-a-2a. The
highest rates of HBeAg seroconversion were achieved by
patients with HBsAg of <1500 IU/mL at week 12 (58%) or
week 24 (57%), whereas patients with HBsAg > 20,000 IU/
mL did not respond.104 In a multinational study of 386
HBeAg-negative patients (mainly with HBV genotype B or C
infection) treated for 48 weeks with PEG-IFN-a-2a with or
without LAM, end-of-treatment serum HBsAg level  10 IU/
mL and on-treatment decline of serum HBsAg level > 1
log10 IU/mL were significantly associated with sustained
HBsAg clearance at 3 years post-treatment.105 Of particular
note is that early decrease of serum HBsAg levels at week
12 was highly predictive of sustained virological response to
PEG-IFN-a-2a.106,107 Similarly, in HBeAg-negative patients
with genotype A and D infection, those with decrease of
serum HBsAg level and decline of HBV DNA > 2 log copies/
mL at week 12 of PEG-IFN-a-2a treatment achieved the
highest probability of sustained virological response.75 In a
long-term follow-up study of HBeAg-negative patients
receiving PEG-IFN-a-2a with or without LAM for 48 weeks,
an on-treatment decline in serum HBsAg level  10% from
baseline at weeks 12 or 24 was significantly associated with
sustained immune control (HBV DNA  2000 IU/mL) at 1
year post-treatment as well as HBsAg clearance 5 years
post-treatment.108 These results indicate that the on-
treatment serum HBsAg level is useful not only to identify
patients who are not likely to benefit from IFN-a earlier,
but also guide optimized treatment duration.109,110 In
addition, serum HBsAg level monitoring after the end of
therapy can help track progress towards sustained
response, and even eventual HBsAg clearance. However,
the prediction rules for PEG-IFN-a therapy based on serum
HBsAg level have not been confirmed across all HBV geno-
types patients, therefore more cohort studies are needed
to prove HBsAg prediction rules for the treatment of
chronic hepatitis B.
In contrast to IFN-based therapy, the role of serum
HBsAg level in patients receiving NA therapy remains
controversial. In a study of 168 HBeAg-positive patients
treated with daily LdT at 600 mg for 3 years, serum HBsAg
level progressively reduced from baseline to year 3 of
therapy (P <0.0001). In addition, 25% of patients with rapid
HBsAg decline (1 log₁₀ IU/mL at year 1) achieved HBsAg
seroclearance at year 3 of therapy compared with none of
those with steady serum HBsAg levels (p Z 0.0024).39 In a
recent study on HBeAg-positive patients treated with ETV,
the majority of patients (60%) had no significant decline in
serum HBsAg levels during 2 years of ETV treatment.
Furthermore, early decline of serum HBsAg levels at 12/24
weeks was not associated with HBV DNA suppression or
HBeAg seroconversion.76 In addition, serum HBsAg levels at
baseline and during antiviral therapy in a limited number of
patients treated with ETV and PEG-IFN-a were compared. In
HBeAg-negative patients, PEG-IFN-a therapy resulted in a
significant reduction in serum HBsAg level, whereas serum
Chronic hepatitis B
Treatment indicated 
Baseline viral 
predictors
assessment
Viral load 
Quantitative HBsAg 
Viral mutants
Genotype 
On-treatment viral predictors
HBeAg-positive patients 
Quantitative HBsAg decline: 
< 1500 IU/mL at week 12 
HBeAg negative patients 
HBV DNA decline: 
 2 log10IU/mL at week 12 
Quantitative HBsAg decline: 
 10% at week 12 
On-treatment viral predictors
HBV DNA decline: 
undetectable at week 24 
Quantitative HBsAg decline: 
 0.5 or 1 log10IU/mL  
at week 24 or 48
Interferon-based therapy Nucleos(t)ide analogs
Figure 1 Hypothetical algorithm for predicting antiviral
treatment response in chronic hepatitis B.
308 C.-L. Lin, J.-H. KaoHBsAg level did not decrease in ETV-treated patients.111
Therefore, whether different antiviral therapies have
different HBsAg kinetics remains unknown. Furthermore,
the time of HBsAg decline during treatment is uncertain.
Therefore, further prospective studies are warranted to
determine the predictive value of HBsAg kinetics for effi-
cacy as well as the optimal time points to measure the
HBsAg level during antiviral treatment.
Conclusions
Accumulating data indicate that long-term HBV suppression
significantly reduced the degree of liver damage and risk of
end-stage liver diseases such as cirrhosis and HCC. A recent
meta-analysis showed that both short-term IFN-based
therapy and long-term NA therapy could improve adverse
outcomes of CHB patients.30,112 During antiviral therapy,
baseline and on-treatment hepatitis B viral factors are
important for the prediction of therapeutic effects (Fig. 1).
On the basis of baseline viral factors, clinicians may select
candidates for IFN-based or NA therapy. Furthermore, on-
treatment predictors may be helpful in making decisions
to stop IFN-based therapy or shift to an alternative therapy.
Although antiviral therapy of CHB has dramatically
improved, eradication of HBV infection is still a challenge.
With the implementation of universal hepatitis B vaccina-
tion, interruption of possible transmission routes and
development of more effective HBV eradication therapy,
HBV eradication is likely to be achieved in the foreseeable
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